Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Roche buys U.S. biotech Jecure in race for liver disease drugs

November 27, 2018 6:28 PM
126 0

ZURICH (Reuters) - Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Roche did not say how much it was paying for Jecure, which gives it a preclinical portfolio of so-called NLRP3 inhibitors being developed for fighting inflammatory diseases like non-alcoholic steatohepatitis (NASH) and liver fibrosis as well as gout, inflammatory bowel disease and cardiovascular dis...

Read more

Share in social networks:

Comments - 0